- Home
- NTCT vs BEAM Comparison
NTCT vs BEAM Comparison
Compare NTCT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTCT
- BEAM
- Stock Information
- Founded
- NTCT 1984
- BEAM 2017
- Country
- NTCT United States
- BEAM United States
- Employees
- NTCT N/A
- BEAM N/A
- Industry
- NTCT EDP Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTCT Technology
- BEAM Health Care
- Exchange
- NTCT Nasdaq
- BEAM Nasdaq
- Market Cap
- NTCT 1.7B
- BEAM 1.6B
- IPO Year
- NTCT 1999
- BEAM 2020
- Fundamental
- Price
- NTCT $23.59
- BEAM $16.76
- Analyst Decision
- NTCT Hold
- BEAM Strong Buy
- Analyst Count
- NTCT 1
- BEAM 11
- Target Price
- NTCT $25.00
- BEAM $48.90
- AVG Volume (30 Days)
- NTCT 387.7K
- BEAM 1.8M
- Earning Date
- NTCT 07-24-2025
- BEAM 08-05-2025
- Dividend Yield
- NTCT N/A
- BEAM N/A
- EPS Growth
- NTCT N/A
- BEAM N/A
- EPS
- NTCT N/A
- BEAM N/A
- Revenue
- NTCT $822,679,000.00
- BEAM $63,578,000.00
- Revenue This Year
- NTCT $3.29
- BEAM N/A
- Revenue Next Year
- NTCT $2.93
- BEAM $8.82
- P/E Ratio
- NTCT N/A
- BEAM N/A
- Revenue Growth
- NTCT N/A
- BEAM N/A
- 52 Week Low
- NTCT $17.67
- BEAM $13.53
- 52 Week High
- NTCT $27.89
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- NTCT 56.65
- BEAM 44.29
- Support Level
- NTCT $23.10
- BEAM $16.18
- Resistance Level
- NTCT $24.05
- BEAM $18.33
- Average True Range (ATR)
- NTCT 0.52
- BEAM 1.10
- MACD
- NTCT -0.05
- BEAM 0.00
- Stochastic Oscillator
- NTCT 60.13
- BEAM 28.65
About NTCT NetScout Systems Inc.
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.